The American Cancer Society projects that in the United States alone in 2024, approximately 13,590 new cases of soft tissue sarcomas (STS) will be diagnosed, with 7,700 cases in males and 5,890 cases in females. Additionally, it is projected that about 5,200 individuals are expected to die from soft tissue sarcomas. It is important to note that these statistics encompass both adults and children.

There are over 80 types of soft tissue sarcoma or sarcoma-like growths. The most common types of sarcomas in adults are undifferentiated pleomorphic sarcoma, Liposarcoma, and Leiomyosarcoma.

For Sarcoma Awareness Month, we will explore the latest guidelines on STS, published by the National Comprehensive Cancer Network (NCCN) in July 2022. Since their publication, two new medications have been approved for treating STS. This article will delve into the changes that have occurred since the guideline’s 2022 release.

Part 1 – Current STS Guidelines

To start, here is a listing of some of the most recent STS treatment and management guidelines published in the US:

Part 2 – FDA Approvals Since the Most Recent Guidelines

The medications/therapies that have been approved by the FDA since the last STS Clinical Guideline:

OGSIVEO® (nirogacestat) tablets

  • SpringWorks Therapeutics, Inc.
  • FDA Approved on November 27, 2023
  • OGSIVEO is a gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment.

TECENTRIQ® (atezolizumab) injection

  • Genentech, Inc.
  • FDA Approved on December 9, 2022
  • TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).

There it is – an overview of the current STS guidelines, updates on recent major changes and FDA approvals that have happened since publication. Are there other topics you would like to see covered in a future guideline series article? Contact us today and let us know!

Copyright © 2024 Guideline Central, All Rights Reserved.